This is an aggregated industry headline. Read the full story at FierceBiotech →
GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its 'priority asset'
Hansoh Pharmaceutical's pair of much-hyped ADCs continue to justify partner GSK's decision to make them priority programs.
By FierceBiotech
· Jul 11, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts' notes and IQVIA data to monitor…
The WeekBriefing
The FDA reported no new hires under PDUFA VII or BsUFA III for FY26 through June, with FY25 and FY24 hiring go…
The WeekSTAT News ↗
Sean Kaufman's views on vaccines may put him at odds with Sen. Bill Cassidy during next week's confirmation he…